In 3-5 years, Piramal Pharma can see 22- 25% EBITDA growth margins: Nandini Piramal

Nandini Piramal projects early teens revenue growth for FY25 and 22-25% EBITDA growth margins in 3-5 years. Revenue increase drives margin expansion through cost optimization and operational excellence, with a focus on CDMO and Indian consumer products growth.